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Abstract
Background: The diagnosis of an acute or convalescent West Nile (WN) virus infection can be
confirmed by various serological assays such as enzyme immunoassay (EIA), immunofluorescence
assay (IFA), or neutralisation test (NT) which are conducted by a growing number of laboratories.
However, as the degree of proficiency may vary between laboratories, quality control measures for
laboratory diagnostics are essential.
Methods: We have performed an external quality assurance (EQA) programme for the serological
detection of WN virus infection to assess the diagnostic quality of laboratories. The participating
laboratories received a proficiency panel of 10 coded lyophilised test samples comprising four
antisera positive for WN antibodies as positive controls, three antisera positive for antibodies
against other heterologous flaviviruses plus one multireactive unspecific serum as specificity
controls, and two negative serum samples.
Results: Twenty-seven laboratories from 20 different countries in Europe, the Middle East, the
Americas and Africa participated in this EQA programme. Applying the proficiency criteria of this
study, only eight laboratories correctly analysed all samples with their respective EIA, IFA or NT
methods. Eighteen laboratories correctly identified between 77.8 and 90% of the samples, and one
laboratory identified only 70% correctly with a clear need to eliminate cross-reactivity with other
antisera, particularly those elicited by yellow fever virus. Differentiation between the results for IgM
and IgG was considered separately and revealed that IgM-antibodies were detected less frequently
than IgG-antibodies (p < 0.001). However, the assay used was not a significant technical factor
influencing laboratory performance.
Conclusion: The EQA programme provides information on the quality of different serological
assays used by the participating laboratories and indicates that most need to improve their assays,
in particular to avoid cross-reactions with antibodies to heterologous flaviviruses.
Published: 3 July 2007
BMC Infectious Diseases 2007, 7:72 doi:10.1186/1471-2334-7-72
Received: 17 January 2007
Accepted: 3 July 2007
This article is available from: http://www.biomedcentral.com/1471-2334/7/72
© 2007 Niedrig et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
BMC Infectious Diseases 2007, 7:72 http://www.biomedcentral.com/1471-2334/7/72Background
West Nile (WN) virus is a mosquito-transmitted flavivirus
which belongs to the Japanese encephalitis virus group. It
occurs throughout Africa, the Middle East, southern
Europe, Russia, India and Indonesia, and was recently
introduced into North America [1-3]. Migratory birds are
involved in the transmission cycle of this virus as amplify-
ing hosts, and humans and horses are considered to be
accidental dead-end hosts [1,4]. In humans, the majority
of WN virus infections cause a non-symptomatic or a mild
flu-like illness. However, some infections can cause
encephalitis which may lead to death, particularly in eld-
erly patients [3]. WN virus is a clear example of the tre-
mendous impact that virus spread and evolution can have
on human beings. From 1999 to 2006 there were 8422
neuroinvasive WN cases (including 889 fatalities)
reported in the United States [5]. The incidence of WN
virus in Europe is comparatively poorly studied and the
risk for a similar epidemic, although low, cannot be pre-
cisely estimated [6]. The availability of reliable serological
assays such as the enzyme immunoassay (EIA), immun-
ofluorescence assay (IFA) or neutralisation test (NT) is an
important prerequisite for the clinical diagnosis and epi-
demiological surveillance of WN virus infections.
A major problem for WN serological assays is their high
degree of cross-reactivity with antibodies produced in
response to other simultaneous and/or previous flavivirus
infections [7]. False positive results are due to the cross-
reactivity of antibodies specific for related epitopes found
on other flaviviruses (e.g. Saint Louis encephalitis-, den-
gue-, yellow fever-, tick-borne encephalitis-, or Japanese
encephalitis virus) induced by natural infection or vacci-
nation. This is mainly true for IgG- and in some cases for
IgM-antibodies. Since differentiation of a specific
immune response is difficult, a fourfold increase in anti-
body titre in follow-up patient sera is mandatory for a
positive diagnosis [8].
Several research laboratories have developed serological
assays for WN virus infection and a number of commer-
cial test kits are now available [9]. However, the perform-
ance of these methods varies considerably between
laboratories. Comprehensive external quality control
studies for WN serology have not yet been performed and
little information is available about the relative and over-
all proficiency in different laboratories. Comparative test-
ing of well-characterised samples is the best method of
identifying weaknesses of single laboratories or of certain
methodological components. The aim of this study was to
assess the diagnostic accuracy across participating labora-
tories and the tests they use by performing the first inter-
national external quality assurance (EQA) study for the
serological detection of WN virus infection.
Methods
Participants and recruitment
Twenty-seven laboratories from 20 different countries
participated in this EQA programme, including 20 labora-
tories from Europe, three from the Middle East, three from
North or South America and one from Africa. A complete
list of participants is given in the acknowledgements sec-
tion. The study was announced as an EQA study on diag-
nostic proficiency run by the European Network for
diagnostics of 'Imported' Viral Diseases (ENIVD), includ-
ing publication of the results in a comparative and anon-
ymous manner. Participation was open and free of charge
to all laboratories performing WN diagnostics. Selection
of invitees was based on the register of ENIVD members
as well as on their contributions to the literature relevant
to this topic.
Preparation of test samples
Test samples for the proficiency panel were generated by
diluting well-characterised human sera with fresh-frozen
plasma tested and confirmed to be negative for HIV, hep-
atitis B-, hepatitis C-, WN- and non-WN-flaviviruses. After
dilution, the enriched serum samples were heat-treated
(56°C, 1 h), frozen and lyophilised in aliquots of 100 µl
to prepare proficiency panels consisting of 10 test sam-
ples. As positive controls the panel comprised aliquots of
four antisera positive for WN antibodies purchased from
SeraCare Life Sciences, Milford, MA, USA. For specificity
controls, aliquots of three antisera containing antibodies
reactive with heterologous flaviviruses (tick-borne
encephalitis-, yellow fever- and Dengue virus) provided
by reference laboratories of our network and one serum
with a known unspecific reactivity against cell and mito-
chondrial structures provided by EUROIMMUN AG,
Lübeck, Germany were included. Two additional aliquots
from confirmed seronegative samples served as negative
controls. Two sets of this EQA panel were tested for spe-
cific activity by two expert laboratories to confirm the
quality of the samples after preparation.
Distribution of test samples and given instructions
All samples were sent out by regular mail and arrived
within 1 week after sending, according to the date of
arrival provided by the participants. It was recommended
that the samples be resuspended with 100 µl distilled
water and centrifuged for 5 min to remove any aggregates
before testing. The participants were asked to analyse the
material by the diagnostic methods they routinely used
for the serological detection of WN virus infection. There
was no obligation concerning the test procedure to be
used but information concerning the type/format (EIA,
IFA, NT) and whether it was an in-house assay or a com-
mercial kit was requested. No further information regard-
ing the detailed processing of the NTs (format, cell linePage 2 of 5
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vided by the participating laboratories.
Evaluation of participants' results
The following two criteria were selected as the minimum
requirements for successful overall proficiency, scored
with 10 points (= 100%). First, laboratories had to detect
the four WN-positive samples irrespective of the differen-
tiation between IgM and IgG; this means that at least one
of these tests had to give a positive result. Second, the
antisera containing cross-reactive antibodies to heterolo-
gous flaviviruses (tick-borne encephalitis-, yellow fever-
and dengue virus) or the known unspecific serum should
not give a positive result and/or should be recognised as
being unspecific. Equivocal or borderline results with the
non-WN-flavivirus positive samples were treated as nega-
tive. The indeterminate result of Lab. No. 15 in one of the
negative samples was identified as such and was not used
in the evaluation. False positive or negative results as well
as non-clarified results with clinical consequences were
given a score of -1. The differentiation between IgM and/
or IgG results was considered separately and gave addi-
tional information concerning the quality of the labora-
tory diagnostics. Data collected were entered into
Microsoft Excel (Microsoft Corp., Bellingham, WA, USA)
and analysed using SPSS 14.0 for Windows. Results with
respect to categorised variables were analysed by the chi-
square test. Whether or not common technical factors or
particular samples influenced the performance of the par-
ticipating laboratories was assessed by univariate and
multivariate logistic regression. A p-value < 0.05 was con-
sidered to indicate statistical significance.
Results and Discussion
Overall proficiency of the participants
Table 1 summarises the results obtained and gives details
on the serological assays used by the participating labora-
tories. Only eight (~30%) of 27 participating laboratories
passed the minimum requirements for successful per-
formance. The main problem of the other laboratories in
achieving the minimum proficiency standards were due to
cross-reactivities with sera containing antibodies to heter-
ologous flaviviruses, mainly with a serum from a yellow
fever vaccinee (14 laboratories; ~52%). Surprisingly, this
sample #7 exhibited cross-reactions in three out of seven
in-house NTs performed by the participants (Table 1).
This demonstrates the limitation of this highly specific
assay and the great variation it could cause in the overall
proficiency, as described previously [10]. However, the
NT is not a suitable assay for rapid diagnosis and should
be combined with an initial detection method. The dis-
tinct cross-reactivity with sera positive for antibodies
against yellow fever virus is a well known difficulty for all
common serological assays and is also mentioned in the
instruction leaflet of the commercial test kits [11]. Poor
performance was also attributable to a lack of sensitivity
in five laboratories (Lab. No. 9, 10, 24, 30, 39) while in
two other laboratories (Lab. No. 11, 17) it was caused by
false positive results, possibly resulting from inadequate
internal controls (Table 1).
Sensitivity for WN specific IgM and IgG antibodies
Of the four clearly WN positive samples, samples #5 and
#6 were identified by nearly all laboratories in all assays
(100% and 96.3%, respectively) whereas samples #8 and
#12 were detected in 88.8% and 81.5% of all analyses per-
formed (Table 1). Interestingly, the detection of IgM anti-
bodies did not correlate with the sensitivity for detecting
IgG antibodies (Table 2). In those laboratories (N = 19)
analysing both the specific IgM and IgG responses, anti-
WN specific IgM activity was correctly identified for sam-
ple #6 by 94.7% (correct negative results), for #5 by
78.9%, for #12 by only 63.2% and #8 by only 57.9% (all
correct positive results). IgM antibodies were detected sig-
nificantly less (p < 0.001) than IgG antibodies with correct
test results between 89.5 and 100% (correct positive
results). The results clearly demonstrate that either the
assays have to be improved or that the assays were not per-
formed correctly. As described in previous EQA studies
[12], these findings indicate that there is a considerable
risk that acute infections are overlooked. Reliable assays
for IgM detection are a prerequisite for the diagnosis of
acute or recent infections in humans and their develop-
ment is therefore very important.
Factors influencing laboratory performance
Nine laboratories used commercial tests (8× West Nile
virus ELISA IgG/IgM test, Focus Diagnostics Inc., Cypress,
CA, USA; 1× West Nile virus ELISA IgG/IgM test, PanBio;
1× West Nile virus IFA kit, PanBio Ltd., Queensland, Aus-
tralia) and 18 laboratories used in-house tests (9× EIA; 6×
IFA and 7× NT). We therefore assessed whether common
technical factors influenced the accuracy of the participat-
ing laboratories. While we found no significant variation
(data not shown) when comparing the two different tech-
nical factors, i.e. assay type/format (EIA vs. IFA vs. NT)
and assay origin (in-house assay vs. commercial assay),
multivariate logistic regression analysis revealed that the
samples used had a significant influence on laboratory
performance (Table 3). Sample #7 showed – compared to
the other samples (except #2, #3 and #5) – a 5- to 33-fold
lower likelihood of correct classification. This result
underlined with statistical significance the analysis of
overall proficiency. The assays tested clearly need to elim-
inate cross-reactivity with antisera positive for related anti-
bodies, particularly those specific for yellow fever virus.
This will be a future objective for the improvement and
development of diagnostic methods for WN virus. As pre-
viously mentioned and in agreement with a previous EQA
study for the serological detection of dengue virus infec-
tion [12,13], there was no significant difference between
the use of commercial or in-house assays.Page 3 of 5
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Table 3: Samples influencing laboratory performance*
Sample p-value Odds-ratio 95% confidence interval
overall 0.001
7 1
1 0.001 10.3 2.6 – 41.4
6 0.001 33.1 4.0 – 275.7
8 0.002 7.4 2.1 – 26.6
10 0.001 10.3 2.6 – 41.4
11 0.001 15.4 3.1 – 76.8
12 0.009 4.6 1.5 – 14.4
* Multivariate logistic regression analyses. All samples shown had a 
significant influence on performance (see text for details).




Fraction of correct 
classified results for 
IgM in %
Fraction of correct 
classified results for 
IgG in %
#8 anti-WN +/+ 57.9 (11) 89.5 (17)
#12 anti-WN +/+ 63.2 (12) 89.5 (17)
#5 anti-WN +/+ 78.9 (15) 100.0 (19)
#6 anti-WN -/+ 94.7 (18) 100.0 (19)
overall: 73.7† 94.7
* No. of laboratories: 19. Number of laboratories with correct results 
shown in brackets.
† IgM-antibodies are less detected than IgG-antibodies (Χ2 = 12.7; p < 
0.001).
Table 1: Overall results of the EQA for the serological detection of WN virus infection
Sample N°
Lab. N° Assay used #8 anti-WN #12 anti-WN #5 anti-
WN
#6 anti-WN #10 anti-TBE #7 anti-YF #11 anti-
DEN




2‡ EIA/IFAih (-)/+ (-)/+ (-)/+ -/+ - - - - - - 100.0
4 EIAih +/+ +/+ +/+ -/+ -* -* - - - - 100.0
8 EIAih +/(-) +/+ +/+ -/+ - -/e - - - - 100.0
18 EIAih +/+ +/+ +/+ -/+ - -* - - - - 100.0
29 IFAih (-)/+ (-)/+ +/+ -/+ - -* - - - - 100.0
37 EIAih + + + + - -* - - - - 100.0
5 EIAF +/+ e/+ +/+ -/+ - -/(+) - - - - 90.0
6 IFAih (-)/+ (-)/+ +/+ -/+ - -/(+) - - - - 90.0
9 IFAP (-) (+)/(+) +/+ -/(+) - -* - - - - 90.0
10 IFAih (-)/+ (-) (-)/+ -/+ - - - - - - 90.0
14 EIAih (-)/+ +/+ (-)/+ -/+ - -/(+) - - - - 90.0
16 EIAF +/+ e/+ +/+ -/+ - -/(+) - - - - 90.0
17 IFAih (-)/+ (-)/+ +/+ -/+ - -/e - - - -/(+) 90.0
20 EIAF +/+ e/+ +/+ -/+ - -/(+) - - - - 90.0
23 EIAF (-)/+ (-)/+ (-)/+ -/+ - -/(+) - - - - 90.0
35 EIAF+P e/+ e/+ e/+ -/+ - -/(+) - - - - 90.0
11 IFAih +/+ +/+ +/+ (+)/+ - -/(+) - - - (+) 80.0
13 EIAF +/+ e/+ e/+ -/+ - -/(+) (+)/- - - - 80.0
24 EIAih + (-) + (-) - - - - - - 80.0
25 EIAF (+)/+ (-)/e (+)/+ -/+ - -/(+) - - - - 80.0
33 EIAih + + + + (+) (+) - - - - 80.0
15 EIAF +/+ +/+ +/+ -/+ (+)/- -/(+) ind. - - - 77.8
30 EIAih (-) (-) + + - (+) - - - - 70.0
7 NTih (+) (+) + + - - - - - - 100.0
36 NTih e + + + - - - - - - 100.0
11 NTih + + + (+) - - - - - (+) 90.0
5 NTih + + + + - (+) (+) - - - 80.0
12 NTih + + + + (+) (+) - - - - 80.0
39 NTih (-) (-) (+) (+) - - - - - - 80.0
30 NTih (-) (-) + + - (+) - - - - 70.0
WN = West Nile; TBE = tick-borne encephalitis; YF = yellow fever; DEN = dengue; neg. = negative; unspec. = unspecific. x/x = IgM/IgG result: - = 
correct negative result; (-) = false negative result without meaning; + = correct positive result; (+) = weak positive result; e = equivocal result; ind. 
= indetermined. -* = negative for WN virus, but other flavivirus detected; -# = negative for WN virus, but unspecific reaction detected. Results 
marked in bold mean false negative/positive results or non conclusive results which may have consequences for the decision of the clinician. ‡ 
Laboratory reported combined results: IgM tested by EIA and IgG tested by IFA. In other cases laboratories have reported combined results for 
IgM and IgG (single results).
EIA: Enzyme immunoassay; IFA: Immunofluorescence assay; NT: neutralisation test. Assays marked with the index "ih" are in-house assays. Assays 
marked in bold are commercial assays. Manufacturers: F = Focus Diagnostics Inc., Cypress, CA; USA, P = PanBio Ltd., Queensland, Australia.
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This study demonstrates the importance of quality control
measures in the serological detection of WN virus infec-
tion. The results clearly indicate a need for certain labora-
tories to improve their tests, e.g. to avoid cross-reactivity
with sera containing antibodies specific for heterologous
flaviviruses. Comparative testing of well-characterised
samples provided all participating laboratories with the
opportunity to identify their weaknesses and to improve
their methodologies, which should then be confirmed in
subsequent studies. However, it is important that new
improved assays with a higher specificity will be devel-
oped that can discriminate between antibody responses to
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